第1章 摘要整理

第2章 調查方法

第3章 市場變數，趨勢，及規模

第4章 市場分析:各治療類型

市場趨勢分析

細胞療法

幹細胞療法

非幹細胞療法

基因治療

CAR-T療法

組織工程產品

第5章 市場分析:各地區

北美

歐洲

亞太地區

其他地區

第6章 競爭情形

策略架構

主要市場參與企業的分類

企業簡介

目錄

Product Code: GVR-3-68038-855-8

The global advanced therapy medicinal products market size is expected to reach USD 9.6 billion by 2026, expanding at a CAGR of 17.4% over the forecast period, according to a new report published by Grand View Research, Inc. The use of advanced therapy medicinal products (ATMPs) is well-proven for the improvement in the quality of life and health status in the long run for patients suffering from life-threatening conditions. This is particularly for diseases with few or no alternative treatment options. These novel treatment modes deliver transformative advantages not offered by conventional forms of disease treatment, thereby driving the ATMP market.

In the current scenario, ATMPs are expensive for patients as well as health insurance schemes. Growing competition to gain revenue share could help reduce prices and improve the affordability, along with the acceptance of these products as mainstream medicine. Furthermore, manufacturers are embracing efforts to streamline technology and logistics for the provision of therapies at accessible prices.

Moreover, lack of manufacturing capabilities to meet growing consumer demand coupled with the resource and budget constraints faced by advanced therapy medicinal product developers has created lucrative avenues for contract services providers and has intensified the market competition. This has led to a rise in market activities by contract service providers. For instance, in November 2019, Fujifilm Diosynth established a 60,000-square-feet Gene Therapy Innovation Center to offer downstream, upstream, and analytical services.

Further key findings from the report suggest:

Cell therapies dominated the ATMP market in 2019, owing to the presence of a substantially high number of approved products for clinical use

Huge investments by commercial and non-commercial sponsors in the testing of cell-based product candidates in clinical studies has also spurred the revenue share of cell therapies

Stem cell-based therapies accounted for the major revenue share in 2019, owing to the high adoption of hematopoietic stem cell transplantation for the treatment of immune system and blood disorders

The recent FDA approval of Zolgensma gene therapy product in May 2019 has accelerated R&D activities in the gene therapy arena, this is anticipated to drive the segment growth at lucrative pace

Similarly, CAR-T therapy is projected to expand at a significant CAGR during the forecast period, resulted by the approval such as Kymriah and Yescarta in the past years

With a high number of approvals of therapies, North America, particularly U.S., captured the largest revenue share in 2019. Increasing marketing operations to sustain the growing market competition coupled with the presence of a relatively high number of candidates in the pipeline is anticipated to propel the U.S. market at a lucrative CAGR in the forthcoming years